samedan logo
 
 
 
spacer
home > pmps > summer 2019 > accurate, precise microlitre dosing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Accurate, Precise Microlitre Dosing

With an ageing population, development of novel therapeutics, and an increasing number of patients with uncontrolled diabetes, the number of microlitre injections is projected to continue to rise. Since 2006, the number of microlitre injections has dramatically increased due to the availability of new treatments for conditions such as agerelated macular degeneration, diabetic macular edema, and vein occlusions. This trend is projected to be replicated with treatments in dermatology, neurology, and oncology; therapeutic treatments include small molecules, monoclonal antibodies, and cell and gene therapies.

Currently, treatments requiring microlitre dosing are primarily administered using hypodermic or insulin syringes. Delivering with these syringes requires the user to draw up the drug into the syringe and align the plunger seal with an external dose marking. It is widely reported in the literature that all syringes currently used for microlitre dosing (50μl or lower) are inaccurate and imprecise. This is because these syringes, indicated for use in general aspiration and dispensing, are operating at the limits of human capability and at the technical limits of the syringe itself.

Additionally, drugs are often stored in these syringes for several months. The lack of availability of syringe-based injection systems that are more suitable for applications requiring microlitre dosing has resulted in several reports of syringe-related adverse events. This problem is compounded by significant off-label use of both syringes and drugs. In early 2018, several reports of sterile intraocular inflammation were reported in the US associated with the injection of certain lots of Eylea®. Subsequently, Regeneron Pharmaceuticals notified clinicians of their decision to not distribute the hypodermic syringe as part of its drug kit. This was a case where even the short residence time of the drug can result in a serious adverse event. Syringebased delivery systems have severely lagged advancements in drug treatments requiring microlitre dosing.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Congruence Medical Solutions, LLC, a privately held company based in Baltimore, Maryland, US, is pioneering development and supply of microlitre injection device systems. Incorporated in 2015, Congruence Medical Solutions has developed its lead product: the Microliter Dosing Syringe (MDS) platform for single microlitre dose applications. With a strong team and a proven track record in injectable drug delivery space, Congruence Medical Solutions aims to supply variants of the MDS and other device platforms to pharma companies. Some variants of the MDS can be available for clinical use as early as January 2020.
spacer
Congruence Medical Solutions
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Byondis’ Investigational Antibody-Drug Conjugate SYD985 Selected for I-SPY 2 TRIAL™ in Early-Stage Breast Cancer

Byondis B.V. (formerly Synthon Biopharmaceuticals) today announced that Quantum Leap Healthcare Collaborative™ (Quantum Leap) selected the company’s investigational antibody-drug conjugate (ADC) SYD985 ([vic-]trastuzumab duocarmazine) for a new investigational treatment arm in its ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement